고객센터
찾아오시는길

HOME > 회원마당 > 보도자료보도자료

개의 줄기세포 소스; 지방, 골수, 난자

미래 | 2018.10.01 11:00 | 조회 7469
September 18, 2018

Preferred Sources for Isolating Stem Cells in Dogs

A recent article reviewed potential tissue sources and applications for stem cell use in veterinary patients.
By Natalie Stilwell, DVM, MS, PhD
stem cell therapyStem cell research has increased significantly in human medicine over the past 20 years, and stem cells derived from sites including bone marrow and adipose tissue are now widely used to treat various diseases. Comparatively, stem cell therapy has been explored minimally in veterinary medicine. Researchers at the Konkuk University’s Center for Stem Cell Research in South Korea recently provided a reviewof mesenchymal stem cell (MSC) therapy in animals.

RELATED: 

Mesenchymal Stem Cells

MSCs differ from hematopoietic stem cells in that they can differentiate into osteoblasts, adipocytes, cardiomyocytes, chondrocytes, hepatocytes, and stem cells. MSCs can be isolated from the following adult, neonatal, and fetal tissues:
  • Bone marrow
  • Adipose tissue
  • Heart
  • Peripheral blood
  • Dermis
  • Umbilical cord blood (UBC)
  • Placenta
  • Amniotic fluid

MSC implantation has been explored for the treatment of a variety of disorders in animals, including atopic dermatitis, osteoarthritis, chronic kidney disease, spinal cord injury, and skin wounds. According to the study authors, an important next step is to determine an ideal tissue source for high yield of MSCs.
 

Umbilical Cord Blood

Collection of MSCs from UCB has been explored primarily in humans, sheep, and horses. Relatively few studies have examined UCB-MSC use in pet animals, including dogs.

While collecting UCB is noninvasive and associated with low morbidity, this source yields significantly fewer MSCs compared with other tissues, such as bone marrow. Human studies showed that UCB-MSC isolation into cell culture media had a low estimated success rate of 26%, but the likelihood of successful isolation relied heavily on obtaining sufficient blood volume. Similarly, UCB-MSC yield in horses, goats, and sheep reportedly increases with increasing blood volume. While some canine studies have successfully isolated MSCs from UCB volumes as low as 8 mL, the authors of the current study reported an average yield of only 1 mL of UCB with a 66% success rate for MSC isolation. Thus, UCB may prove to be an unreliable source of stem cells in canine subjects.

Another important consideration is that UCB can only be obtained during C-section in the dog, as the bitch typically consumes the placenta and umbilical cord during natural birth. While 1 study reported higher MSC yields from fetal heart tissue, this method is more invasive and raises ethical concerns. Therefore, the authors stated that alternative options to neonatal and fetal tissues should be explored.
 

Adipose and Reproductive Tissues

Adipose tissue can also be used for MSC collection, as cells from this source can differentiate into adipogenic, osteogenic, and chrondrogenic types. Interestingly, reproductive tissues also yield high numbers of MSCs. Although ovaries and testes are frequently discarded as medical waste during sterilization, both tissues are “proven to be potent and reliable sources of MSCs,” according to the authors. Both also have the same multipotent potential as do adipose-derived MSCs. Therefore, the authors recommended future use of reproductive and adipose tissues, rather than UCB, for MSC collection in veterinary medicine.   

 
Dr. Stilwell received her DVM from Auburn University, followed by a MS in fisheries and aquatic sciences and a PhD in veterinary medical sciences from the University of Florida. She provides freelance medical writing and aquatic veterinary consulting services through her business, Seastar Communications and Consulting.

Sign up to receive the latest news in veterinary medicine.
보도자료
번호 제목 글쓴이 조회 날짜
125 "줄기세포로 코로나19로 손상된 폐 치료가능" 학계 주장에 눈길 관리자 206 2020.04.20
124 줄기세포로 '코로나19' 치료 가능할까... 관리자 181 2020.04.20
123 [포스트 코로나]이희영 대한줄기세포치료학회장, 관리자 165 2020.04.20
122 줄기세포 배양문제 해결? 코로나19 치료 해답 이희영 회장, “의사 자율.. 관리자 174 2020.04.20
121 '줄기세포 치료 활성화' 첨단재생바이오법 입법예고 관리자 171 2020.04.20
120 [현장에서] ‘백신·치료제보다 줄기세포’ 코로나19, 맹장 수술비용으로 .. 관리자 118 2020.04.20
119 줄기세포치료학회 관리자 116 2020.04.20
118 "긴급한 코로나19 환자에 줄기세포 치료 적용해야" 관리자 111 2020.04.20
117 "변이 많은 코로나19, 줄기세포 치료가 대안" 관리자 125 2020.04.20
116 "줄기세포로 손상된 폐 재생…코로나19 치료 효과적" 관리자 116 2020.04.20
115 이희영 회장 “치료제·백신 개발 변수많아… 줄기세포 치료가 우선” Ss 135 2020.04.20
114 [TF사진관] '줄기세포 코로나19 치료 가능하다' Ss 128 2020.04.20
113 줄기세포 주사, 면역력 강화에 도움 줄 수 있어 Ss 204 2020.04.14
112 줄기세포 코로나19 치료제 후보 급부상 Ss 242 2020.04.14
111 지방으로 코로나를? 한인 2세, 줄기세포 치료제 눈길 Ss 196 2020.04.14
110 치료제 없는 코로나19…국내 의료진의 긴급처방은? Ss 91 2020.04.14
109 Transplantation of ACE2- Mesenchymal Ste.. 관리자 69 2020.04.06
108 Mesenchymal stem cells and management of.. 관리자 65 2020.04.06
107 Stem cells may give a respite to COVID-1.. 관리자 62 2020.04.06
106 Stem Cell Therapy for COVID-19 Is Gainin.. 관리자 59 2020.04.06